| 2,839 | 6 | 68 |
| 下载次数 | 被引频次 | 阅读次数 |
糖尿病肾脏疾病(Diabetic kidney disease, DKD)是糖尿病最严重的微血管并发症之一，其发病原因具有高度复杂性，涉及多种体内途径和肾外因素的影响。组学技术是基于高通量测序和检测的一系列分析技术，主要包括蛋白质组学、代谢组学、转录组学和基因组学等。现代药理研究中，单一组学研究虽然可以在一定程度上加深对DKD病理病机的了解，但尚不能全面阐明DKD病机间的多重性和关联性。而多组学联用则可以通过复杂的通路和网络关联来整合不同组学的数据，揭示各组学之间的调控关系，进而探究中医药干预DKD发生发展的相关机制，为发展新的治疗策略提供可能。本文旨在通过讨论单组学技术和多组学联用在中医药治疗DKD的作用和机制研究中的应用情况，为临床治疗DKD提供新思路、新方法。
Abstract：Diabetic kidney disease(DKD) is one of the most serious microvascular complications of diabetes, and its pathogenesis is highly complex, involving multiple in vivo pathways and extrarenal factors. Omics technology is a series of analysis technologies based on high-throughput sequencing and detection, mainly including proteomics, metabolomics, transcriptomics, and genomics. By reviewing the modern pharmacological research, it is found that although single-omics research deepens the understanding of the pathogenesis of DKD to a certain extent, it cannot fully clarify the multiplicity and correlation among the pathogenesis of DKD. The multi-omics combination integrates the data of different omics through complex pathways and networks, and reveals the regulatory relationship among each single omics, thus exploring the related mechanism of Chinese medicine intervention in the occurrence and development of DKD. The multi-omics combination provides possibilities for the development of new treatment strategies. This article discussed the effect of using single-omics technology and multi-omics combination on the treatment of DKD with Chinese medicine and the mechanism, thereby providing new ideas and new methods for clinical treatment of DKD.
[1]Reiner Robert-C,Olsen Helen-Elizabeth,Ikeda Chad-Thomas,et al.Diseases,Injuries,and Risk Factors in Child and Adolescent Health,1990 to 2017:Findings From the Global Burden of Diseases,Injuries,and Risk Factors 2017 Study[J].JAMA pediatrics,2019,(6):e190337.
[2]Chen Ya,Lee Kyung,Ni Zhaohui,et al.Diabetic Kidney Disease:Challenges,Advances,and Opportunities[J].Kidney diseases (Basel,Switzerland),2020,(4):215-225.
[3]Ducasa G M,Mitrofanova A,Mallela S K,et al.Atp-binding Cassette A1 Deficiency Causes Cardiolipin-driven Mitochondrial Dysfunction in Podocytes[J].J Clin Invest,2019,129(8):3387-3400.
[4]CHEN A,FENG Y,LAI H,et al.Soluble Rarres1 Induces Podocyte Apoptosis to Promote Glomerular Disease Progression[J].J Clin Invest,2020,130(10):5523-5535.
[5]ZHANG B L,YANG X H,JIN H M,et al.Identification of Differentially Expressed Genes in Diabetic Kidney Disease By Rna-seq Analysis of Venous Blood Platelets[J].Febs Open Bio,2021,11(8):2095-2109.
[6]WEI Y,GAO X,LI A,et al.Single-nucleus Transcriptomic Analysis Reveals Important Cell Cross-talk in Diabetic Kidney Disease[J].Front Med (lausanne),2021,8:657956.
[7]CUI C,CUI Y,FU Y,et al.Microarray Analysis Reveals Gene and Microrna Signatures in Diabetic Kidney Disease.[J].Mol Med Rep,2017(2):2161-2168.
[8]Carlsson A C,Nowak C,Lind L,et al.Growth Differentiation Factor 15 (gdf-15) Is a Potential Biomarker of Both Diabetic Kidney Disease and Future Cardiovascular Events in Cohorts of Individuals with Type 2 Diabetes:a Proteomics Approach[J].Ups J Med Sci,2019,125(1):37-43.
[9]Santana M F M,Lira A L A,Pinto R S,et al.Enrichment of Apolipoprotein A-iv and Apolipoprotein D in the Hdl Proteome Is Associated with Hdl Functions in Diabetic Kidney Disease Without Dialysis[J].Lipids Health Dis,2020,19(1):205.
[10]Golea-secara A,Munteanu C,Sarbu M,et al.Urinary Proteins Detected Using Modern Proteomics Intervene in Early Type 2 Diabetic Kidney Disease-a Pilot Study[J].Biomark Med,2020,14(16):1521-1536.
[11]Brondani L D A,Soares A A,Recamonde-mendoza M,et al.Urinary Peptidomics and Bioinformatics for the Detection of Diabetic Kidney Disease[J].Sci Rep,2020,10(1):1242.
[12]王旭方，李梦婕，葛永纯，等.糖尿病肾病患者血清及尿液代谢组学特点及临床意义[J].肾脏病与透析肾移植杂志，2012,21(3):201-209.
[13]Tan Y M,Gao Y,Teo G,et al.Plasma Metabolome and Lipidome Associations with Type 2 Diabetes and Diabetic Nephropathy[J].Metabolites,2021,11(4):228.
[14]JIANG H,SHAO X,JIA S,et al.The Mitochondria-targeted Metabolic Tubular Injury in Diabetic Kidney Disease[J].Cell Physiol Biochem,2019,52(2):156-171.
[15]MA T,LIU T,XIE P,et al.Uplc-ms-based Urine Nontargeted Metabolic Profiling Identifies Dysregulation of Pantothenate and Coa Biosynthesis Pathway in Diabetic Kidney Disease[J].Life Sci,2020,258:118160.
[16]Mutter S,Valo E,Aittom?ki V,et al.Urinary Metabolite Profiling and Risk of Progression of Diabetic Nephropathy in 2670 Individuals with Type 1 Diabetes[J].Diabetologia,2022,65(1):140-149.
[17]Lecamwasam A,Nelson T M,Rivera L,et al.Gut Microbiome Composition Remains Stable in Individuals with Diabetes-related Early to Late Stage Chronic Kidney Disease[J].Biomedicines,2020,9(1):19.
[18]YU W,SHANG J,GUO R,et al.The Gut Microbiome in Differential Diagnosis of Diabetic Kidney Disease and Membranous Nephropathy[J].Ren Fail,2020,42(1):1100-1110.
[19]Salguero M V,Al-obaide M A I,Singh R,et al.Dysbiosis of Gram-negative Gut Microbiota and the Associated Serum Lipopolysaccharide Exacerbates Inflammation in Type 2 Diabetic Patients with Chronic Kidney Disease[J].Exp Ther Med,2019(5):3461-3469.
[20]Blanchet L,Smolinska A,Attali A,et al.Fusion of Metabolomics and Proteomics Data for Biomarkers Discovery:Case Study on the Experimental Autoimmune Encephalomyelitis[J].Bmc Bioinformatics,2011,12(1):254.
[21]LIU S,GUI Y,WANG M S,et al.Serum Integrative Omics Reveals the Landscape of Human Diabetic Kidney Disease[J].Mol Metab,2021,54:101367.
[22]Rossi C,Marzano V,Consalvo A,et al.Proteomic and Metabolomic Characterization of Streptozotocin-induced Diabetic Nephropathy in Timp3-deficient Mice[J].Acta Diabetol,2017,55(2):121-129.
[23]Kammer M,Heinzel A,Willency J,et al.Integrative Analysis of Prognostic Biomarkers Derived From Multiomics Panels Helps Discrimination of Chronic Kidney Disease Trajectories in People with Type 2 Diabetes[J].Kidney Int,2019,96(6):1381-1388.
[24]Tan S,Ziemann M,Thallas-bonke V,et al.Complement C5a Induces Renal Injury in Diabetic Kidney Disease By Disrupting Mitochondrial Metabolic Agility[J].Diabetes,2019,69(1):83-98.
[25]Sha Q,Lyu J,Zhao M,et al.Multi-omics Analysis of Diabetic Nephropathy Reveals Potential New Mechanisms and Drug Targets[J].Front Genet,2020,11:616435.
[26]Abdalla M,Abdalla M,Siddiqi F S,et al.A Common Glomerular Transcriptomic Signature Distinguishes Diabetic Kidney Disease From Other Kidney Diseases in Humans and Mice[J].Curr Res Transl Med,2020,68(4):225-236.
[27]Winther S,Henriksen P,Vogt J,et al.Gut Microbiota Profile and Selected Plasma Metabolites in Type 1 Diabetes Without and with Stratification By Albuminuria[J].Diabetologia,2020,63(12):2713-2724.
[28]Li Y,Chen X,Kwan T,et al.Dietary Fiber Protects Against Diabetic Nephropathy Through Short-chain Fatty Acid-mediated Activation of G Protein-coupled Receptors Gpr43 and Gpr109a[J].J Am Soc Nephrol,2020,31(6):1267-1281.
[29]胡作为，周燕萍，沈自尹.从现代生物学的发展谈中医药从整体上调控基因功能的优势[J].中医药学刊，2004(1):91-93.
[30]中医药治疗糖尿病肾病临床与基础研究——中日友好医院临床医学研究所李平教授团队学术研究进展[J].世界科学技术-中医药现代化，2017,19(4):530-541.
[31]王宏献.早期糖尿病肾病中医证候与尿液蛋白质组学的关系研究[D].浙江中医药大学，2013.
[32]QIAN J,YIN S,YE L,et al.An Indole-2-carboxamide Derivative,Lg4,Alleviates Diabetic Kidney Disease Through Inhibiting Mapk-mediated Inflammatory Responses[J].J Inflamm Res,2021,( 14) 1633-1645.
[33]WANG J,ZHANG Q,LI S,et al.Low Molecular Weight Fucoidan Alleviates Diabetic Nephropathy By Binding Fibronectin and Inhibiting Ecm-receptor Interaction in Human Renal Mesangial Cells[J].Int J Biol Macromol,2020,150:304-314.
[34]LI T,YANG Y,WANG X,et al.Flavonoids Derived From Buckwheat Hull Can Break Advanced Glycation End-products and Improve Diabetic Nephropathy[J].Food Funct,2021,12(16):7161-7170.
[35]于欢，黎莉，梁琼麟，等.代谢组学应用于糖肾方治疗糖尿病肾病的疗效评价[J].色谱，2011,29(4):320-324.
[36]黄敏，朱超，梁琼麟，等.中药糖肾方调节糖尿病肾病患者磷脂代谢研究[J].药学学报，2011,46(7):780-786.
[37]QIN X,JIANG M,ZHAO Y,et al.Berberine Protects Against Diabetic Kidney Disease Via Promoting Pgc-1α-regulated Mitochondrial Energy Homeostasis[J].Br J Pharmacol,2020,177(16):3646-3661.
[38]王英明，李建省，闫燕顺，等.肠道菌群与慢性肾衰竭的相互作用及中药干预研究进展[J].中国实验方剂学杂志：1-11.
[39]冯程程，藏登，陈茜，等.糖肾灌肠方经肠道干预糖尿病肾病小鼠模型的肠道菌群研究[J].实用中医内科杂志：1-12.
[40]LI Z,JIA R,WU J,et al.Sargassum Fusiforme Polysaccharide Partly Replaces Acarbose Against Type 2 Diabetes in Rats[J].Int J Biol Macromol,2020,170:447-458.
[41]YANG J,DONG H,WANG Y,et al.Cordyceps Cicadae Polysaccharides Ameliorated Renal Interstitial Fibrosis in Diabetic Nephropathy Rats By Repressing Inflammation and Modulating Gut Microbiota Dysbiosis[J].Int J Biol Macromol,2020,163:442-456.
[42]LI X,CHEN H,HE Y,et al.Effects of Rich-polyphenols Extract of Dendrobium Loddigesii on Anti-diabetic,Anti-inflammatory,Anti-oxidant,and Gut Microbiota Modulation in Db/db Mice[J].Molecules,2018,23(12):3245.
[43]蔡红蝶，宿树兰，郭建明，等.丹参对糖尿病肾损伤大鼠肠道菌群多样性的影响[J].中国中药杂志，2021,46(2):426-435.
[44]蔺建忠，张磊，王丹，等.参麦注射液联合贝前列素钠片对糖尿病肾病炎症因子及血流动力学的影响[J].中医研究，2020,33(10):14-19.
[45]尹德辉，朱叶，吴珠，等.缩泉益肾方对糖尿病肾脏疾病患者的血清炎症因子及肾功能的影响[J].时珍国医国药，2021,32(8):1931-1933.
[46]Naito Y,Uchiyama K,Handa O,et al.Therapeutic Potential of Astaxanthin in Diabetic Kidney Disease[Z]:Springer Singapore,2021:239-248.
[47]Zhong Y,Lee K,Deng Y,et al.Arctigenin Attenuates Diabetic Kidney Disease Through the Activation of Pp2a in Podocytes[J].Nat Commun,2019,10(1):4523.
[48]XIAO Y,LIU Y,LAI Z,et al.An Integrated Network Pharmacology and Transcriptomic Method to Explore the Mechanism of the Total Rhizoma Coptidis Alkaloids in Improving Diabetic Nephropathy[J].J Ethnopharmacol,2021,270:113806.
[49]黄志强.基于网络药理学的UCG及糖肾方的作用靶点预测及机制探讨[D].广东药科大学，2017.
基本信息:
DOI：10.13412/j.cnki.zyyl.20220610.001
中图分类号:R285
引用信息:
[1]孟雨帆,吴宿慧,李寒冰,等.多组学联用技术在中药治疗糖尿病肾病中的作用和机制研究进展[J].中药药理与临床,2024,40(01):97-102.DOI:10.13412/j.cnki.zyyl.20220610.001.
基金信息:
国家重点研发计划项目(编号：2020YFE0201800); 河南省科技攻关计划(编号：212102310347)
2022-06-10
2022-06-10
2022-06-10